X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PSIL-006 is a non-hallucinogenic serotonin receptor 6 (5-HT6) and 2A (5-HT2A) dual agonist that selectively reduces hallucinogenic effects while retaining rapid therapeutic benefits.
Lead Product(s): PSIL-006
Therapeutic Area: Psychiatry/Psychology Product Name: PSIL-006
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
N,N-dimethyltryptamine and psilocybin-like prodrug, psilacetin, patch formulations are designed for patient comfort and useability. The patch design could provide a non-invasive and dose-controlled method of treatment for substance use disorders, PTSD and depression.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2022
Details:
PSIL-001 (N,N-Dimethyltryptamine) and PSIL-002 showed similar preclinical efficacy to psilacetin, a positive control, in the forced swim test depression model without hallucinations via the head twitch response.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: PSIL-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
